The CIEN Research Center will have a significant presence at the LXXVI Annual Meeting of the Spanish Society of Neurology (SEN), to be held in Valencia from November 19 to 23, 2024. A multidisciplinary team of researchers from CIEN will bring to the congress a series of innovative studies addressing some of the most relevant topics in the field of neurodegenerative diseases.
The CIEN presentation program includes crucial advances in areas such as biomarkers, neuroimaging, and neuropathology, presented in various formats such as oral communications, seminars, and written presentations.
Among the key studies to be presented are those on biomarkers in Alzheimer's disease, pathology associated with dementia with Lewy bodies, and hippocampal sclerosis research. Additionally, advances in understanding genetic interactions and their implications in diseases such as dementia and Alzheimer's will be discussed.
This study investigates the relationship between hippocampal volume and TDP-43 levels in extracellular vesicles as biomarkers for diagnosing LATE and hippocampal sclerosis, two pathologies related to aging and neurodegeneration.
This study explores neurodegeneration patterns in amnestic patients who do not show typical signs on Tau-PET scans, a neuroimaging technique used to detect tau protein in the brain, which is implicated in Alzheimer's disease. The research focuses on identifying alternative forms of neurodegeneration, such as LATE, which may not be visible with conventional tools.
This presentation addresses the complex interaction between Alzheimer's disease and dementia with Lewy bodies. The researchers analyze the clinical and neurobiological characteristics of patients presenting with amnesia and copathologies, complicating the diagnosis and proper treatment of these neurodegenerative diseases.
This study investigates the genetics behind susceptibility to Alzheimer's disease, specifically the APOE-ε4 gene, known to increase the risk of developing the disease. The research explores how heterozygosity in the KLOTHO-VS gene, a gene related to healthy aging, may mitigate the effects of APOE-ε4 on hippocampal atrophy, one of the most affected areas in Alzheimer's.
A seminar in which Pascual Sánchez-Juan, CIEN's scientific director, will discuss national challenges for managing and preventing Alzheimer's disease in Spain. The talk will focus on preparing the healthcare system to address the growing number of cases and on scientific and clinical advances that may improve patient outcomes.
Mario Ricciardi's seminar focuses on cerebral amyloid angiopathy (CAA) and ARIAs (adverse effects related to Alzheimer's disease treatment), addressing the latest definitions, diagnostic criteria, and their clinical relevance.
This study examines cholinergic tracts, areas of the brain involved in cognitive function, in patients with Alzheimer's, dementia with Lewy bodies, and other neurodegenerative diseases. Using post-mortem MRI, the researchers aim to understand how these tracts are affected in various diseases.
This study uses blood levels of p-tau217 as a biomarker to predict cognitive progression in cognitively healthy elderly individuals. The work is part of the Vallecas Project, a longitudinal study following individuals over several years to understand how certain biomarkers can predict future cognitive decline.
This work explores how the presence of multiple neurodegenerative pathologies can affect blood biomarkers used to diagnose and monitor diseases such as Alzheimer's, Parkinson's, and dementia. Researchers analyze the interaction of different pathologies and their influence on blood biomolecular profiles.
This study addresses cerebral amyloid angiopathy (CAA), a condition associated with Alzheimer's disease in which amyloid protein accumulates in brain blood vessels. The study investigates how certain blood markers may help detect this pathology in early stages, improving diagnosis and treatment of the disease.
In this seminar, Pascual Sánchez-Juan will discuss digital biomarkers, those obtained through technological devices like smartwatches, and their potential application in clinical practice to monitor and diagnose neurodegenerative diseases.
This poster analyzes the impact of neurodegenerative copathologies on the cognitive performance of patients, a crucial topic to improve understanding of how the presence of multiple pathologies can alter cognition in diseases like Alzheimer's, Parkinson's, and others.
This study investigates the relationship between semantic fluency (the ability to generate words related to a topic) and mobility parameters in the elderly. It analyzes how cognitive and motor deterioration may be interrelated in older adults.
This study focuses on kidney insufficiency's role in influencing plasma biomarker levels in dementia patients. It aims to determine how renal dysfunction can impact the measurement of biomarkers critical for diagnosing neurodegenerative diseases.
This session investigates how the deposits of amyloid beta (Aβ) and tau proteins, hallmarks of Alzheimer's disease, affect cognitive abilities in individuals with early-onset Alzheimer's.
This session discusses the latest advances in imaging biomarkers used to diagnose neurodegenerative diseases early, such as Alzheimer's and Parkinson's. It reviews different imaging techniques like PET and MRI and their clinical application.
En este seminario, los investigadores exploran cómo la atrofia multisistémica, una enfermedad neurodegenerativa rara, se combina con otras patologías en el cerebro, complicando tanto el diagnóstico como el tratamiento de las enfermedades en pacientes con copatologías.